DAFTAR PUSTAKA

Alianto, R. (2018) ‘Perbedaan Nilai Rerata Agnor Antara Hiperplasia Endometrium Non-Atipik, Endometrioid Intraepithelial Neoplasia, Dan Karsinoma Endometrioid Endometrium’.

American Cancer Society (2022) ‘Bauchspeicheldrüsenkrebs - Heilungschancen minimal’, *Deutsches Arzteblatt*, pp. 255–262. doi: 10.3238/arztebl.2008.0255.

Bakkum-gamez, J. N. and Wentzensen, N. (2018) ‘Association of Endometrial Cancer Risk With Postmenopausal Bleeding in Women A Systematic Review and Meta-analysis’, 178(9), pp. 1210–1222. doi: 10.1001/jamainternmed.2018.2820.

Berg, A. *et al.* (2015) ‘Molecular profiling of endometrial carcinoma precursor, primary and metastatic lesions suggests different targets for treatment in obese compared to non-obese patients’, *Oncotarget*, 6(2), pp. 1327–1339. doi: 10.18632/oncotarget.2675.

Bhaskaran, K. *et al.* (2014) ‘Body-mass index and risk of 22 specific cancers: a population-based cohort study of 5·24 million UK adults’, *The Lancet*, 384(9945), pp. 755–765. doi: 10.1016/S0140-6736(14)60892-8.

Bladder, C. *et al.* (2023) ‘Bladder Cancer Early Detection , Diagnosis , and Staging Can Bladder Cancer Be Found Early’, *American Cancer Society*, (cancer.org), pp. 1–24. Available at: https://www.cancer.org/content/dam/CRC/PDF/Public/8661.00.pdf.

Bray, F., Ferlay, J. and Soerjomataram, I. (2018) ‘Global Cancer Statistics 2018 : GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries’, pp. 394–424. doi: 10.3322/caac.21492.

Chatsirisupachai, K., Lagger, C. and de Magalhães, J. P. (2022) ‘Age-associated differences in the cancer molecular landscape’, *Trends in Cancer*, 8(11), pp. 962–971. doi: 10.1016/j.trecan.2022.06.007.

Chen, H. *et al.* (2017) ‘Hepatic cyclooxygenase-2 overexpression induced spontaneous hepatocellular carcinoma formation in mice’, *Oncogene*, 36(31), pp. 4415–4426. doi: 10.1038/onc.2017.73.

Chen, Q. *et al.* (2015) 'Parity correlates with the timing of developing endometrial cancer, but not subtype of endometrial cancer', *Journal of Cancer*, 6(11), pp. 1087–1092. doi: 10.7150/jca.12736.

Colombo, N. *et al.* (2016) 'ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer', 26(1), pp. 2–30. doi: 10.1097/IGC.0000000000000609.

Coopes, A. and Henry, C. E. (2018) 'An update of Wnt signalling in endometrial cancer and its potential as a therapeutic target'.

Cormio, A. *et al.* (2012) 'Mitochondrial DNA content and mass increase in progression from normal to hyperplastic to cancer endometrium', *BMC Research Notes*, 5(1), p. 1. doi: 10.1186/1756-0500-5-279.

Deng, L., Liang, H. and Han, Y. (2020) 'Cyclooxygenase-2 and β-Catenin as Potential Diagnostic and Prognostic Markers in Endometrial Cancer', *Frontiers in Oncology*, 10(February), pp. 1–10. doi: 10.3389/fonc.2020.00056.

Domingues, P. *et al.* (2015) 'Genetic/molecular alterations of meningiomas and the signaling pathways targeted', *Oncotarget*, 6(13), pp. 10671–10688. doi: 10.18632/oncotarget.3870.

Emelia Rahmadany (2018) 'UNIVERSITAS SUMATERA UTARA Poliklinik UNIVERSITAS SUMATERA UTARA', *Jurnal Pembangunan Wilayah & Kota*, 1(3), pp. 82–91.

Eritja, N. *et al.* (2017) *Endometrial Carcinoma : Specifi c Targeted Pathways*. doi: 10.1007/978-3-319-43139-0.

Ferrandina, G. *et al.* (2002) 'Cyclooxygenase-2 expression in endometrial carcinoma: Correlation with clinicopathologic parameters and clinical outcome', *Cancer*, 95(4), pp. 801–807. doi: 10.1002/cncr.10736.

Fotopoulou, C. and Gabra, H. (2014) 'Endometrial cancer', *Treatment of Cancer, Sixth Edition*, pp. 405–416. doi: 10.1201/b17751-20.

Fowler, J. M. *et al.* (2005) 'Correlation of cyclooxygenase-2 (COX-2) and aromatase expression in human endometrial cancer: Tissue microarray analysis', *American Journal of Obstetrics and Gynecology*, 192(4), pp. 1262–1271. doi: 10.1016/j.ajog.2005.01.009.

Globocan, 360-indonesia-fact-sheetsy (2020) ‘273 523 621’, 858, pp. 2020–2021.

Hag-Yahia, N. *et al.* (2021a) ‘Age is an independent predictor of outcome in endometrial cancer patients: An Israeli Gynecology Oncology Group cohort study’, *Acta Obstetricia et Gynecologica Scandinavica*, 100(3), pp. 444–452. doi: 10.1111/aogs.14015.

Hag-Yahia, N. *et al.* (2021b) ‘Age is an independent predictor of outcome in endometrial cancer patients: An Israeli Gynecology Oncology Group cohort study’, *Acta Obstetricia et Gynecologica Scandinavica*, 100(3), pp. 444–452. doi: 10.1111/aogs.14015.

Hapangama, D. K., Kamal, A. M. and Bulmer, J. N. (2015) ‘Estrogen receptor b: The guardian of the endometrium’, *Human Reproduction Update*, 21(2), pp. 174–193. doi: 10.1093/humupd/dmu053.

Hashemi Goradel, N. *et al.* (2019) ‘Cyclooxygenase-2 in cancer: A review’, *Journal of Cellular Physiology*, 234(5), pp. 5683–5699. doi: 10.1002/jcp.27411.

Hasna, N. *et al.* (2019) ‘Prevalensi Mioma Uteri dengan Koeksistensi Hiperplasia Endometrium The Prevalence of Uterine Fibroid with Endometrial Hyperplasia Coexistence’, 14, pp. 30–38.

Hidayati, M. U., Mulawardhana, P. and Kurniasari, N. (2021) ‘Risk Factors for Estrogen Exposure in Various Grades of Endometrioid Carinoma’, *Indonesian Midwifery and Health Sciences Journal*, 4(1), pp. 40–50. doi: 10.20473/imhsj.v4i1.2020.40-50.

Jiao, Y. *et al.* (2020) ‘Assessment of early damage of endometrium after artificial abortion by shear wave elastography’, *Insights into Imaging*, 11(1). doi: 10.1186/s13244-020-0841-4.

Juhamran, M. J. (2018) ‘Hubungan Ekpresi Cycloxygenase-2 (COX-2) dengan Disease Free Surivival dan Overall Survival pada Penderita Kanker Payudara’, 2.

Kiewisz, J., Wasniewski, T. and Kmiec, Z. (2015) ‘Participation of WNT and ? -Catenin in Physiological and Pathological Endometrial Changes : Association with Angiogenesis’, 2015(19).

Landen, C. N. *et al.* (2003) ‘Expression of cyclooxygenase-2 in cervical, endometrial,

and ovarian malignancies', *American Journal of Obstetrics and Gynecology*, 188(5), pp. 1174–1176. doi: 10.1067/mob.2003.284.

Li, F. and Zhu, Y. T. (2015) 'HGF-activated colonic fibroblasts mediates carcinogenesis of colonic epithelial cancer cells via PKC-cMET-ERK1/2-COX-2 signaling', *Cellular Signalling*, 27(4), pp. 860–866. doi: 10.1016/j.cellsig.2015.01.014.

Liu, L. *et al.* (2023) 'Differential trends in rising endometrial cancer incidence by age, race, and ethnicity', *JNCI Cancer Spectrum*, 7(1), pp. 1–4. doi: 10.1093/jncics/pkad001.

Lortet-tieulent, J. *et al.* (2018) 'International Patterns and Trends in Endometrial Cancer Incidence , 1978 – 2013', 110, pp. 354–361. doi: 10.1093/jnci/djx214.

Lyndin, M. *et al.* (2022) 'COX2 Effects on endometrial carcinomas progression', *Pathology Research and Practice*, 238, p. 154082. doi: 10.1016/j.prp.2022.154082.

Ma, X., Ma, C. X. and Wang, J. (2014) 'Endometrial Carcinogenesis and Molecular Signaling Pathways', (July), pp. 134–149.

Manule, Y. *et al.* (2019) 'Hubungan ekspresi β-Catenin (β -catenin) dengan derajat histopatologi pada karsinoma endometrium tipe i', 1(2), pp. 87–91.

Marret, H. *et al.* (2010) 'Clinical practice guidelines on menorrhagia: Management of abnormal uterine bleeding before menopause', *European Journal of Obstetrics and Gynecology and Reproductive Biology*, 152(2), pp. 133–137. doi: 10.1016/j.ejogrb.2010.07.016.

Mirhalina, S. (2020) 'Jenis dan Faktor Risiko Kanker Endometrium Di Rumah Sakit dr Pirngadi Kota Medan Tahun 2015-2018', *Jurnal Pandu Husada*, 1(3), p. 184. doi: 10.30596/jph.v1i3.4944.

Ohno, S. *et al.* (2005) 'Multiple roles of cyclooxygenase-2 in endometrial cancer', *Anticancer Research*, 25(6 A), pp. 3679–3687.

Pistolesi, S. *et al.* (2007) 'Expression of cyclooxygenase-2 and its correlation with vasogenic brain edema in human intracranial meningiomas', *Cancer Investigation*, 25(7), pp. 555–562. doi: 10.1080/07357900701508280.

Puspitasari, F. D., Hoesin, F. and Fauziah, D. (2014) 'Ekspresi Endometrium dan

pada Karsinogenesis', 23(1), pp. 42–47.

Robbins & Cotran pathologic basic and disease 10th, ed 2. (2021).

Saegusa, M. *et al.* (2001) 'B-Catenin Mutations and Aberrant Nuclear Expression During Endometrial Tumorigenesis', *British Journal of Cancer*, 84(2), pp. 209–217. doi: 10.1054/bjoc.2000.1581.

Sarkar, S. *et al.* (2018) 'Study of Beta-Catenin Expression : In Endometrial Hyperplasia and Carcinoma', *Annals of Pathology and Laboratory Medicine, Vol. 5, Issue 7, July, 2018*, pp. 1–7. doi: 10.21276/APALM.1899.

Shih, H., Shiozawa, T. and Miyamoto, T. (2004) 'Immunohistochemical expression of E-cadherin and beta-catenin', *Anticancer Research*, 24(6), pp. 3843–3850. Available at: https://pubmed.ncbi.nlm.nih.gov/15736420/.

Siegel, R. L., Miller, K. D. and Jemal, A. (2018) 'Cancer Statistics , 2018', 68(1), pp. 7–30. doi: 10.3322/caac.21442.

Suparman, Erna and Suparman, Eddy (2014) 'Peran Estrogen Dan Progesteron Terhadap Kanker Payudara', *Jurnal Biomedik (Jbm)*, 6(3), pp. 141–148. doi: 10.35790/jbm.6.3.2014.6319.

Wang, Y. *et al.* (2009) 'Progesterone inhibition of Wnt/β-catenin signaling in normal endometrium and endometrial cancer', *Clinical Cancer Research*, 15(18), pp. 5784–5793. doi: 10.1158/1078-0432.CCR-09-0814.

Wang, Y. *et al.* (2010) 'Wnt/B-catenin and sex hormone signaling in endometrial homeostasis and cancer.', *Oncotarget*, 1(7), pp. 674–684. doi: 10.18632/oncotarget.201.

Wu, Q. J. *et al.* (2015) 'Parity and endometrial cancer risk: A meta-analysis of epidemiological studies', *Scientific Reports*, 5, pp. 1–17. doi: 10.1038/srep14243.

Xiong, W. *et al.* (2015) 'Estradiol promotes cells invasion by activating β-catenin signaling pathway in endometriosis', *Reproduction*, 150(6), pp. 507–516. doi: 10.1530/REP-15-0371.

Xu, W. and Kimelman, D. (2007) 'Mechanistic insights from structural studies of beta -catenin and its binding partners'. doi: 10.1242/jcs.013771.

Lampiran

KEMENTERIAN PENDIDIKAN, KEBUDAYAAN, RISET DAN TEKNOLOGI
UNIVERSITAS HASANUDDIN FAKULTAS KEDOKTERAN
KOMITE ETIK PENELITIAN UNIVERSITAS HASANUDDIN
RSPTN UNIVERSITAS HASANUDDIN
RSUP Dr. WAHIDIN SUDIROHUSODO MAKASSAR
Sekretariat : Lantai 2 Gedung Laboratorium Terpadu
JL.PERINTIS KEMERDEKAAN KAMPUS TAMALANREA KM.10 MAKASSAR 90245.
Contact Person: dr. Agussalim Bukhari.,MMed,PhD, SpGK TELP. 081241850858, 0411 5780103, Fax : 0411-581431

REKOMENDASI PERSETUJUAN ETIK

Nomor : 822/UN4.6.4.5.31/ PP36/ 2022

Tanggal: 15 Desember 2022

Dengan ini Menyatakan bahwa Protokol dan Dokumen yang Berhubungan Dengan Protokol berikut ini telah mendapatkan Persetujuan Etik :

No Protokol	UH22120755	No Sponsor Protokol	
Peneliti Utama	**dr. Aries Maulana**	Sponsor	
Judul Peneliti	Ekspresi Cyclooxygenase-2 (Cox-2) Dan ?-Catenin Pada Hiperplasia Endometrium Atipik Dan Non Atipik Sebagai Prediktor Potensial Carcinoma Endometrium Tipe Endometrioid		
No Versi Protokol	**1**	Tanggal Versi	**15 Desember 2022**
No Versi PSP		Tanggal Versi	
Tempat Penelitian	RS Universitas Hasanuddin Makassar		
Jenis Review	[x] Exempted [ ] Expedited [ ] Fullboard Tanggal	Masa Berlaku **15 Desember 2022** sampai **15 Desember 2023**	Frekuensi review lanjutan
Ketua KEP Universitas Hasanuddin	Nama **Prof.Dr.dr. Suryani As'ad, M.Sc.,Sp.GK (K)**	Tanda tangan	
Sekretaris KEP Universitas Hasanuddin	Nama **dr. Agussalim Bukhari, M.Med.,Ph.D.,Sp.GK (K)**	Tanda tangan	

Kewajiban Peneliti Utama:

- Menyerahkan Amandemen Protokol untuk persetujuan sebelum di implementasikan
- Menyerahkan Laporan SAE ke Komisi Etik dalam 24 Jam dan dilengkapi dalam 7 hari dan Lapor SUSAR dalam 72 Jam setelah Peneliti Utama menerima laporan
- Menyerahkan Laporan Kemajuan (progress report) setiap 6 bulan untuk penelitian resiko tinggi dan setiap setahun untuk penelitian resiko rendah
- Menyerahkan laporan akhir setelah Penelitian berakhir
- Melaporkan penyimpangan dari prokol yang disetujui (protocol deviation / violation)
- Mematuhi semua peraturan yang ditentukan

Tests of Normality

	Kolmogorov-Smirnov[a]			Shapiro-Wilk		
	Statistic	df	Sig.	Statistic	df	Sig.
Umur	.077	90	.200*	.984	90	.343
Berat Badan	.110	90	.009	.971	90	.045
Tinggi Badan	.147	90	.000	.939	90	.000
BMI	.176	90	.000	.934	90	.000
Intentitas Beta Catenin	.475	90	.000	.524	90	.000
Persentase Beta Catenin	.147	90	.000	.924	90	.000
Luas Area Beta Catenin	.397	90	.000	.664	90	.000
Intentitas COX2	.313	90	.000	.757	90	.000
Persentase COX2	.284	90	.000	.732	90	.000
Luas Area COX2	.306	90	.000	.780	90	.000
H-Score Beta Catenin	.144	90	.000	.925	90	.000
H-Score COX2	.294	90	.000	.698	90	.000

*. This is a lower bound of the true significance.

a. Lilliefors Significance Correction

Descriptive Statistics

	N	Minimum	Maximum	Mean	Std. Deviation
Umur	90	23	66	45.07	9.072
Paritas	90	.00	5.00	2.2111	1.25863
Aborsi	90	.00	3.00	.3556	.60543
Berat Badan	90	35.00	89.00	61.8667	12.38811
Tinggi Badan	90	1.40	1.76	1.5046	.07259
BMI	90	17.86	41.19	27.3254	5.22275
Intentitas Beta Catenin	90	2.00	3.00	2.7667	.42532
Persentase Beta Catenin	90	.10	.90	.6056	.22851
Luas Area Beta Catenin	90	1.00	3.00	2.6000	.55688
Intentitas COX2	90	.00	2.00	.6556	.73685
Persentase COX2	90	.00	.70	.1350	.19145
Luas Area COX2	90	.00	3.00	.7667	.88749
H-Score Beta Catenin	90	20.00	270.00	173.8889	72.94287
H-Score COX2	90	.00	140.00	18.6111	29.11646
Valid N (listwise)	90				

Uji Kualitatif Chi-Square Intensitas B-Catenin - Binnary

Case Processing Summary

	Cases					
	Valid		Missing		Total	
	N	Percent	N	Percent	N	Percent
Klass2 * Intensitas BC	90	100.0%	0	0.0%	90	100.0%

Klass2 * Intensitas BC Crosstabulation

Count

		Intensitas BC		Total
		1.00	2.00	
Klass2	Non Atipik	12	20	32
	Atipik dan Karsinoma	9	49	58
Total		21	69	90

Chi-Square Tests

	Value	df	Asymp. Sig. (2-sided)	Exact Sig. (2-sided)	Exact Sig. (1-sided)
Pearson Chi-Square	5.571[a]	1	.018		
Continuity Correction[b]	4.410	1	.036		
Likelihood Ratio	5.386	1	.020		
Fisher's Exact Test				.035	.019
Linear-by-Linear Association	5.509	1	.019		
N of Valid Cases	90				

a. 0 cells (,0%) have expected count less than 5. The minimum expected count is 7,47.

b. Computed only for a 2x2 table

Uji Kualitatif Chi-Square Intensitas COX-2 (*Fischer Exact)-Binnary

Case Processing Summary

	Cases					
	Valid		Missing		Total	
	N	Percent	N	Percent	N	Percent
Klass2 * Intensitas COX	90	100.0%	0	0.0%	90	100.0%

Klass2 * Intensitas COX Crosstabulation

Count

		Intensitas COX		
		Positif (bila skor dua dan tiga)	Negatif (bila skor nol dan satu)	Total
Klass2	Non Atipik	1	31	32
	Atipik dan Karsinoma	13	45	58
Total		14	76	90

Chi-Square Tests

	Value	df	Asymp. Sig. (2-sided)	Exact Sig. (2-sided)	Exact Sig. (1-sided)
Pearson Chi-Square	5.841[a]	1	.016		
Continuity Correction[b]	4.465	1	.035		
Likelihood Ratio	7.178	1	.007		
Fisher's Exact Test				.016	.012
Linear-by-Linear Association	5.776	1	.016		
N of Valid Cases	90				

a. 1 cells (25,0%) have expected count less than 5. The minimum expected count is 4,98.

Oneway

Descriptives

Umur

	N	Mean	Std. Deviation	Std. Error	95% Confidence Interval for Mean	
					Lower Bound	Upper Bound
Non Atipik	32	44.97	6.151	1.087	42.75	47.19
Atipik	27	40.33	10.333	1.989	36.25	44.42
Carcinoma	31	49.29	8.599	1.544	46.14	52.44
Total	90	45.07	9.072	.956	43.17	46.97

ANOVA

Umur

	Sum of Squares	df	Mean Square	F	Sig.
Between Groups	1158.244	2	579.122	8.169	.001
Within Groups	6167.356	87	70.889		
Total	7325.600	89			

ANOVA Effect Sizes[a]

		Point Estimate	95% Confidence Interval	
			Lower	Upper
Umur	Eta-squared	.158	.034	.284
	Epsilon-squared	.139	.012	.268
	Omega-squared Fixed-effect	.137	.012	.266
	Omega-squared Random-effect	.074	.006	.153

a. Eta-squared and Epsilon-squared are estimated based on the fixed-effect model.

Multiple Comparisons

Dependent Variable: Umur

	(I) Class	(J) Class	Mean Difference (I-J)	Std. Error	Sig.	95% ... Lower Bound
LSD	Non Atipik	Atipik	4.635*	2.200	.038	.26
		Carcinoma	-4.322*	2.122	.045	-8.54
	Atipik	Non Atipik	-4.635*	2.200	.038	-9.01
		Carcinoma	-8.957*	2.216	.000	-13.36
	Carcinoma	Non Atipik	4.322*	2.122	.045	.10
		Atipik	8.957*	2.216	.000	4.55
Games-Howell	Non Atipik	Atipik	4.635	2.266	.114	-.88
		Carcinoma	-4.322	1.889	.066	-8.87
	Atipik	Non Atipik	-4.635	2.266	.114	-10.15
		Carcinoma	-8.957*	2.518	.002	-15.04
	Carcinoma	Non Atipik	4.322	1.889	.066	-.23
		Atipik	8.957*	2.518	.002	2.88

Independent-Samples Kruskal-Wallis Test

Paritas across Class

Independent-Samples Kruskal-Wallis Test Summary

Total N	90
Test Statistic	4.580[a]
Degree Of Freedom	2
Asymptotic Sig.(2-sided test)	.101

a. The test statistic is adjusted for ties.



Pairwise Comparisons of Class

Sample 1-Sample 2	Test Statistic	Std. Error	Std. Test Statistic	Sig.	Adj. Sig.[a]
Atipik-Non Atipik	5.966	6.603	.903	.366	1.000
Atipik-Carcinoma	-14.111	6.652	-2.121	.034	.102
Non Atipik-Carcinoma	-8.145	6.368	-1.279	.201	.603

Each row tests the null hypothesis that the Sample 1 and Sample 2 distributions are the same.

Asymptotic significances (2-sided tests) are displayed. The significance level is ,050.

a. Significance values have been adjusted by the Bonferroni correction for multiple tests.



Aborsi across Class

Independent-Samples Kruskal-Wallis Test Summary

Total N	90
Test Statistic	2.358[a]
Degree Of Freedom	2
Asymptotic Sig.(2-sided test)	.308

a. The test statistic is adjusted for ties.



Pairwise Comparisons of Class

Sample 1-Sample 2	Test Statistic	Std. Error	Std. Test Statistic	Sig.	Adj. Sig.[a]
Non Atipik-Atipik	-4.372	5.463	-.800	.424	1.000
Non Atipik-Carcinoma	-8.078	5.268	-1.533	.125	.376
Atipik-Carcinoma	-3.706	5.503	-.673	.501	1.000

Each row tests the null hypothesis that the Sample 1 and Sample 2 distributions are the same.
Asymptotic significances (2-sided tests) are displayed. The significance level is ,050.

a. Significance values have been adjusted by the Bonferroni correction for multiple tests.



BMI across Class

Independent-Samples Kruskal-Wallis Test Summary

Total N	90
Test Statistic	4.903[a]
Degree Of Freedom	2
Asymptotic Sig.(2-sided test)	.086

a. The test statistic is adjusted for ties.



Pairwise Comparisons of Class

Sample 1-Sample 2	Test Statistic	Std. Error	Std. Test Statistic	Sig.	Adj. Sig.[a]
Non Atipik-Carcinoma	-10.102	6.578	-1.536	.125	.374
Non Atipik-Atipik	-14.547	6.821	-2.133	.033	.099
Carcinoma-Atipik	4.446	6.871	.647	.518	1.000

Each row tests the null hypothesis that the Sample 1 and Sample 2 distributions are the same.
Asymptotic significances (2-sided tests) are displayed. The significance level is ,050.

a. Significance values have been adjusted by the Bonferroni correction for multiple tests.



Chi-Square Indeks Massa Tubuh

Crosstab

Count

		Class			
		Non Atipik	Atipik	Carcinoma	Total
Klasifikasi BMI	Underweight	0	0	1	1
	Normal	19	10	13	42
	Overweight	3	4	1	8
	Obese	10	13	16	39
Total		32	27	31	90

Chi-Square Tests

	Value	df	Asymptotic Significance (2-sided)	Exact Sig. (2-sided)	Exact Sig. (1-sided)	Point Probability
Pearson Chi-Square	7.603[a]	6	.269	.241		
Likelihood Ratio	8.057	6	.234	.252		
Fisher-Freeman-Halton Exact Test	7.385			.234		
Linear-by-Linear Association	1.649[b]	1	.199	.221	.112	.023
N of Valid Cases	90					

a. 6 cells (50.0%) have expected count less than 5. The minimum expected count is .30.

b. The standardized statistic is 1.284.

Binnary- Indeks Massa Tubuh

Crosstab

Count

		Non Atipik Vs Atipik + Carcinoma		
		Non Atipik	Atipik + Carcinoma	Total
BMI Binary	0.00	22	29	51
	1.00	10	29	39
Total		32	58	90

Chi-Square Tests

	Value	df	Asymptotic Significance (2-sided)	Exact Sig. (2-sided)	Exact Sig. (1-sided)	Point Probability
Pearson Chi-Square	2.952[a]	1	.086	.120	.067	
Continuity Correction[b]	2.238	1	.135			
Likelihood Ratio	3.007	1	.083	.120	.067	
Fisher's Exact Test				.120	.067	
Linear-by-Linear Association	2.920[c]	1	.088	.120	.067	.041
N of Valid Cases	90					

a. 0 cells (0.0%) have expected count less than 5. The minimum expected count is 13.87.

b. Computed only for a 2x2 table

c. The standardized statistic is 1.709.

Risk Estimate

	Value	95% Confidence Interval	
		Lower	Upper
Odds Ratio for BMIBinary (.00 / 1.00)	2.200	.888	5.452
For cohort Non Atipik Vs Atipik + Carcinoma = Non Atipik	1.682	.905	3.129

Intentitas Beta Catenin across Class

Independent-Samples Kruskal-Wallis Test Summary

Total N	90
Test Statistic	11.050[a]
Degree Of Freedom	2
Asymptotic Sig.(2-sided test)	.004

a. The test statistic is adjusted for ties.



Pairwise Comparisons of Class

Sample 1-Sample 2	Test Statistic	Std. Error	Std. Test Statistic	Sig.	Adj. Sig.[a]
Non Atipik-Carcinoma	-8.120	4.823	-1.683	.092	.277
Non Atipik-Atipik	-16.615	5.001	-3.322	.001	.003
Carcinoma-Atipik	8.495	5.038	1.686	.092	.275

Each row tests the null hypothesis that the Sample 1 and Sample 2 distributions are the same.
Asymptotic significances (2-sided tests) are displayed. The significance level is ,050.

a. Significance values have been adjusted by the Bonferroni correction for multiple tests.



Persentase Beta Catenin across Class

Independent-Samples Kruskal-Wallis Test Summary

Total N	90
Test Statistic	9.558[a]
Degree Of Freedom	2
Asymptotic Sig.(2-sided test)	.008

a. The test statistic is adjusted for ties.



Pairwise Comparisons of Class

Sample 1-Sample 2	Test Statistic	Std. Error	Std. Test Statistic	Sig.	Adj. Sig.[a]
Non Atipik-Carcinoma	-15.335	6.518	-2.353	.019	.056
Non Atipik-Atipik	-19.477	6.758	-2.882	.004	.012
Carcinoma-Atipik	4.142	6.808	.608	.543	1.000

Each row tests the null hypothesis that the Sample 1 and Sample 2 distributions are the same.
Asymptotic significances (2-sided tests) are displayed. The significance level is ,050.

a. Significance values have been adjusted by the Bonferroni correction for multiple tests.



Luas Area Beta Catenin across Class

Independent-Samples Kruskal-Wallis Test Summary

Total N	90
Test Statistic	9.683[a]
Degree Of Freedom	2
Asymptotic Sig.(2-sided test)	.008

a. The test statistic is adjusted for ties.



Pairwise Comparisons of Class

Sample 1-Sample 2	Test Statistic	Std. Error	Std. Test Statistic	Sig.	Adj. Sig.[a]
Non Atipik-Carcinoma	-12.135	5.543	-2.189	.029	.086
Non Atipik-Atipik	-17.161	5.748	-2.986	.003	.008
Carcinoma-Atipik	5.027	5.791	.868	.385	1.000

Each row tests the null hypothesis that the Sample 1 and Sample 2 distributions are the same.
Asymptotic significances (2-sided tests) are displayed. The significance level is ,050.

a. Significance values have been adjusted by the Bonferroni correction for multiple tests.



H-Score Beta Catenin across Class

Independent-Samples Kruskal-Wallis Test Summary

Total N	90
Test Statistic	11.744[a]
Degree Of Freedom	2
Asymptotic Sig.(2-sided test)	.003

a. The test statistic is adjusted for ties.



Pairwise Comparisons of Class

Sample 1-Sample 2	Test Statistic	Std. Error	Std. Test Statistic	Sig.	Adj. Sig.[a]
Non Atipik-Carcinoma	-15.290	6.532	-2.341	.019	.058
Non Atipik-Atipik	-22.444	6.773	-3.314	.001	.003
Carcinoma-Atipik	7.154	6.823	1.049	.294	.883

Each row tests the null hypothesis that the Sample 1 and Sample 2 distributions are the same.
Asymptotic significances (2-sided tests) are displayed. The significance level is ,050.

a. Significance values have been adjusted by the Bonferroni correction for multiple tests.



Intentitas COX2 across Class

Independent-Samples Kruskal-Wallis Test Summary

Total N	90
Test Statistic	13.600[a]
Degree Of Freedom	2
Asymptotic Sig.(2-sided test)	.001

a. The test statistic is adjusted for ties.



Pairwise Comparisons of Class

Sample 1-Sample 2	Test Statistic	Std. Error	Std. Test Statistic	Sig.	Adj. Sig.[a]
Non Atipik-Atipik	-11.646	6.221	-1.872	.061	.184
Non Atipik-Carcinoma	-22.109	6.000	-3.685	.000	.001
Atipik-Carcinoma	-10.463	6.267	-1.670	.095	.285

Each row tests the null hypothesis that the Sample 1 and Sample 2 distributions are the same.
Asymptotic significances (2-sided tests) are displayed. The significance level is ,050.

a. Significance values have been adjusted by the Bonferroni correction for multiple tests.



Persentase COX2 across Class

Independent-Samples Kruskal-Wallis Test Summary

Total N	90
Test Statistic	11.043[a]
Degree Of Freedom	2
Asymptotic Sig.(2-sided test)	.004

a. The test statistic is adjusted for ties.



Pairwise Comparisons of Class

Sample 1-Sample 2	Test Statistic	Std. Error	Std. Test Statistic	Sig.	Adj. Sig.[a]
Non Atipik-Atipik	-12.215	6.366	-1.919	.055	.165
Non Atipik-Carcinoma	-20.254	6.140	-3.299	.001	.003
Atipik-Carcinoma	-8.039	6.413	-1.253	.210	.630

Each row tests the null hypothesis that the Sample 1 and Sample 2 distributions are the same.
Asymptotic significances (2-sided tests) are displayed. The significance level is ,050.

a. Significance values have been adjusted by the Bonferroni correction for multiple tests.



Luas Area COX2 across Class

Independent-Samples Kruskal-Wallis Test Summary

Total N	90
Test Statistic	9.120[a]
Degree Of Freedom	2
Asymptotic Sig.(2-sided test)	.010

a. The test statistic is adjusted for ties.



Pairwise Comparisons of Class

Sample 1-Sample 2	Test Statistic	Std. Error	Std. Test Statistic	Sig.	Adj. Sig.[a]
Non Atipik-Atipik	-12.233	6.287	-1.946	.052	.155
Non Atipik-Carcinoma	-17.924	6.063	-2.956	.003	.009
Atipik-Carcinoma	-5.692	6.333	-.899	.369	1.000

Each row tests the null hypothesis that the Sample 1 and Sample 2 distributions are the same.
Asymptotic significances (2-sided tests) are displayed. The significance level is ,050.

a. Significance values have been adjusted by the Bonferroni correction for multiple tests.



H-Score COX2 across Class

Independent-Samples Kruskal-Wallis Test Summary

Total N	90
Test Statistic	12.362[a]
Degree Of Freedom	2
Asymptotic Sig.(2-sided test)	.002

a. The test statistic is adjusted for ties.



Pairwise Comparisons of Class

Sample 1-Sample 2	Test Statistic	Std. Error	Std. Test Statistic	Sig.	Adj. Sig.[a]
Non Atipik-Atipik	-12.542	6.375	-1.967	.049	.147
Non Atipik-Carcinoma	-21.511	6.148	-3.499	.000	.001
Atipik-Carcinoma	-8.968	6.422	-1.396	.163	.488

Each row tests the null hypothesis that the Sample 1 and Sample 2 distributions are the same.
Asymptotic significances (2-sided tests) are displayed. The significance level is ,050.

a. Significance values have been adjusted by the Bonferroni correction for multiple tests.



Oneway

Descriptives

		N	Mean	Std. Deviation	Std. Error
Umur	Non Atipik	32	44.97	6.151	1.087
	Atipik	27	40.33	10.333	1.989
	Carcinoma	31	49.29	8.599	1.544
	Total	90	45.07	9.072	.956
Paritas	Non Atipik	32	2.1875	1.25563	.22197
	Atipik	27	1.9259	1.26873	.24417
	Carcinoma	31	2.4839	1.23480	.22178
	Total	90	2.2111	1.25863	.13267
Aborsi	Non Atipik	32	.2188	.42001	.07425
	Atipik	27	.4074	.74726	.14381
	Carcinoma	31	.4516	.62390	.11206
	Total	90	.3556	.60543	.06382
Berat Badan	Non Atipik	32	60.4688	11.48346	2.03001
	Atipik	27	64.5926	11.70555	2.25273
	Carcinoma	31	60.9355	13.80564	2.47957
	Total	90	61.8667	12.38811	1.30582
Tinggi Badan	Non Atipik	32	1.5256	.08339	.01474
	Atipik	27	1.5056	.06947	.01337
	Carcinoma	31	1.4819	.05712	.01026
	Total	90	1.5046	.07259	.00765

Descriptives

		N	Mean	Std. Deviation	Std. Error
BMI	Non Atipik	32	26.1150	5.37368	.94994
	Atipik	27	28.4786	4.79187	.92220
	Carcinoma	31	27.5704	5.32549	.95649
	Total	90	27.3254	5.22275	.55053
Intentitas Beta Catenin	Non Atipik	32	2.5938	.49899	.08821
	Atipik	27	2.9630	.19245	.03704
	Carcinoma	31	2.7742	.42502	.07634
	Total	90	2.7667	.42532	.04483
Persentase Beta Catenin	Non Atipik	32	.5094	.22627	.04000
	Atipik	27	.6815	.18818	.03622
	Carcinoma	31	.6387	.23477	.04217
	Total	90	.6056	.22851	.02409
Luas Area Beta Catenin	Non Atipik	32	2.4063	.49899	.08821
	Atipik	27	2.7778	.50637	.09745
	Carcinoma	31	2.6452	.60819	.10923
	Total	90	2.6000	.55688	.05870
Intentitas COX2	Non Atipik	32	.3125	.53506	.09459
	Atipik	27	.6667	.73380	.14122
	Carcinoma	31	1.0000	.77460	.13912
	Total	90	.6556	.73685	.07767
Persentase COX2	Non Atipik	32	.0594	.13164	.02327
	Atipik	27	.1519	.19438	.03741
	Carcinoma	31	.1984	.21813	.03918
	Total	90	.1350	.19145	.02018
Luas Area COX2	Non Atipik	32	.4375	.80071	.14155
	Atipik	27	.8519	.90739	.17463
	Carcinoma	31	1.0323	.87498	.15715
	Total	90	.7667	.88749	.09355
H-Score Beta Catenin	Non Atipik	32	138.1250	75.79418	13.39865
	Atipik	27	204.0741	57.66343	11.09733
	Carcinoma	31	184.5161	68.30513	12.26796
	Total	90	173.8889	72.94287	7.68885
H-Score COX2	Non Atipik	32	6.5625	14.28046	2.52445
	Atipik	27	20.0000	28.11378	5.41050
	Carcinoma	31	29.8387	36.50306	6.55614
	Total	90	18.6111	29.11646	3.06914

Multiple Comparisons

Dependent Variable		(I) Class	(J) Class	Sig.	95% ... Lower Bound
Umur	LSD	Non Atipik	Atipik	.038	.26
			Carcinoma	.045	-8.54
		Atipik	Non Atipik	.038	-9.01
			Carcinoma	.000	-13.36
		Carcinoma	Non Atipik	.045	.10
			Atipik	.000	4.55
	Games-Howell	Non Atipik	Atipik	.114	-.88
			Carcinoma	.066	-8.87
		Atipik	Non Atipik	.114	-10.15
			Carcinoma	.002	-15.04
		Carcinoma	Non Atipik	.066	-.23
			Atipik	.002	2.88
Paritas	LSD	Non Atipik	Atipik	.426	-.3889
			Carcinoma	.350	-.9237
		Atipik	Non Atipik	.426	-.9121
			Carcinoma	.094	-1.2132
		Carcinoma	Non Atipik	.350	-.3310
			Atipik	.094	-.0974
	Games-Howell	Non Atipik	Atipik	.709	-.5332
			Carcinoma	.614	-1.0501
		Atipik	Non Atipik	.709	-1.0564
			Carcinoma	.218	-1.3527
		Carcinoma	Non Atipik	.614	-.4574
			Atipik	.218	-.2368
Aborsi	LSD	Non Atipik	Atipik	.235	-.5020
			Carcinoma	.129	-.5360
		Atipik	Non Atipik	.235	-.1247
			Carcinoma	.781	-.3589
		Carcinoma	Non Atipik	.129	-.0693
			Atipik	.781	-.2714
	Games-Howell	Non Atipik	Atipik	.480	-.5828
			Carcinoma	.203	-.5571
		Atipik	Non Atipik	.480	-.2065
			Carcinoma	.968	-.4843
		Carcinoma	Non Atipik	.203	-.0914
			Atipik	.968	-.3959
Berat Badan	LSD	Non Atipik	Atipik	.206	-10.5623
			Carcinoma	.882	-6.6758
		Atipik	Non Atipik	.206	-2.3146
			Carcinoma	.265	-2.8287

Multiple Comparisons

Dependent Variable		(I) Class	(J) Class	Sig.	95% ... Lower Bound
		Atipik	Non Atipik	.001	.1367
			Carcinoma	.078	-.0172
		Carcinoma	Non Atipik	.277	-.0999
			Atipik	.078	-.3947
Persentase Beta Catenin	LSD	Non Atipik	Atipik	.003	-.2857
			Carcinoma	.021	-.2389
		Atipik	Non Atipik	.003	.0585
			Carcinoma	.460	-.0717
		Carcinoma	Non Atipik	.021	.0198
			Atipik	.460	-.1572
	Games-Howell	Non Atipik	Atipik	.006	-.3020
			Carcinoma	.075	-.2690
		Atipik	Non Atipik	.006	.0423
			Carcinoma	.723	-.0911
		Carcinoma	Non Atipik	.075	-.0103
			Atipik	.723	-.1766
Luas Area Beta Catenin	LSD	Non Atipik	Atipik	.010	-.6526
			Carcinoma	.083	-.5100
		Atipik	Non Atipik	.010	.0904
			Carcinoma	.354	-.1505
		Carcinoma	Non Atipik	.083	-.0322
			Atipik	.354	-.4158
	Games-Howell	Non Atipik	Atipik	.018	-.6881
			Carcinoma	.213	-.5766
		Atipik	Non Atipik	.018	.0549
			Carcinoma	.639	-.2198
		Carcinoma	Non Atipik	.213	-.0988
			Atipik	.639	-.4851
Intentitas COX2	LSD	Non Atipik	Atipik	.051	-.7102
			Carcinoma	.000	-1.0308
		Atipik	Non Atipik	.051	-.0018
			Carcinoma	.068	-.6920
		Carcinoma	Non Atipik	.000	.3442
			Atipik	.068	-.0253
	Games-Howell	Non Atipik	Atipik	.104	-.7656
			Carcinoma	.000	-1.0931
		Atipik	Non Atipik	.104	-.0573
			Carcinoma	.221	-.8107
		Carcinoma	Non Atipik	.000	.2819
			Atipik	.221	-.1440

Multiple Comparisons

Dependent Variable		(I) Class	(J) Class	Sig.	95% ... Lower Bound
Persentase COX2	LSD	Non Atipik	Atipik	.058	-.1881
			Carcinoma	.004	-.2312
		Atipik	Non Atipik	.058	-.0031
			Carcinoma	.339	-.1428
		Carcinoma	Non Atipik	.004	.0468
			Atipik	.339	-.0498
	Games-Howell	Non Atipik	Atipik	.102	-.1993
			Carcinoma	.010	-.2491
		Atipik	Non Atipik	.102	-.0143
			Carcinoma	.668	-.1770
		Carcinoma	Non Atipik	.010	.0289
			Atipik	.668	-.0839
Luas Area COX2	LSD	Non Atipik	Atipik	.068	-.8607
			Carcinoma	.007	-1.0252
		Atipik	Non Atipik	.068	-.0320
			Carcinoma	.427	-.6300
		Carcinoma	Non Atipik	.007	.1643
			Atipik	.427	-.2692
	Games-Howell	Non Atipik	Atipik	.166	-.9566
			Carcinoma	.018	-1.1030
		Atipik	Non Atipik	.166	-.1278
			Carcinoma	.724	-.7465
		Carcinoma	Non Atipik	.018	.0865
			Atipik	.724	-.3857
H-Score Beta Catenin	LSD	Non Atipik	Atipik	.000	-101.3654
			Carcinoma	.008	-80.5457
		Atipik	Non Atipik	.000	30.5328
			Carcinoma	.279	-16.1188
		Carcinoma	Non Atipik	.008	12.2366
			Atipik	.279	-55.2347
	Games-Howell	Non Atipik	Atipik	.001	-107.8257
			Carcinoma	.035	-90.0369
		Atipik	Non Atipik	.001	24.0724
			Carcinoma	.469	-20.2700
		Carcinoma	Non Atipik	.035	2.7453
			Atipik	.469	-59.3859
H-Score COX2	LSD	Non Atipik	Atipik	.067	-27.8347
			Carcinoma	.001	-37.1605
		Atipik	Non Atipik	.067	-.9597
			Carcinoma	.181	-24.3418